eIF4B Inhibitors are a class of compounds that target the eukaryotic initiation factor 4B (eIF4B), a critical component of the translation initiation machinery in eukaryotic cells. eIF4B plays a key role in facilitating the recruitment of ribosomes to messenger RNA (mRNA), a process that is essential for the synthesis of proteins. Specifically, eIF4B enhances the helicase activity of eIF4A, another initiation factor, which unwinds secondary structures in the 5' untranslated region (UTR) of mRNA. This unwinding is necessary for the small ribosomal subunit to scan the mRNA and locate the start codon, thereby initiating translation. Inhibitors of eIF4B disrupt this process, potentially leading to a reduction in global protein synthesis, as well as selective effects on the translation of specific mRNAs that are particularly dependent on eIF4B activity.
Research into eIF4B Inhibitors is valuable for understanding the regulation of translation, a fundamental process that controls gene expression at the post-transcriptional level. By inhibiting eIF4B, scientists can investigate the effects on mRNA translation, especially those mRNAs with complex secondary structures in their 5' UTRs, which are more reliant on eIF4B for efficient translation. This can provide insights into how cells control the synthesis of proteins in response to various stimuli and conditions, such as stress, nutrient availability, and signaling pathways. Additionally, eIF4B is known to interact with other components of the translation initiation complex, including eIF3 and the cap-binding protein eIF4E, so its inhibition may shed light on the broader network of interactions that regulate translation initiation. Understanding these interactions is crucial for unraveling the complexities of translational control and its impact on cellular function, growth, and adaptation. Researchers can use eIF4B Inhibitors as tools to dissect these processes, thereby contributing to a deeper knowledge of how cells regulate protein production in both normal and altered states.
VOIR ÉGALEMENT...
Items 11 to 16 of 16 total
Afficher:
Nom du produit | CAS # | Ref. Catalogue | Quantité | Prix HT | CITATIONS | Classement |
---|---|---|---|---|---|---|
Doxorubicin | 23214-92-8 | sc-280681 sc-280681A | 1 mg 5 mg | $173.00 $418.00 | 43 | |
Les dommages à l'ADN causés par la doxorubicine peuvent amener la cellule à donner la priorité à la réparation de l'ADN par rapport aux fonctions régulières, supprimant potentiellement la machinerie ARNi et diminuant les niveaux d'eIF2C2. | ||||||
Camptothecin | 7689-03-4 | sc-200871 sc-200871A sc-200871B | 50 mg 250 mg 100 mg | $57.00 $182.00 $92.00 | 21 | |
L'inhibition de la topoisomérase I par la camptothécine peut causer des dommages à l'ADN, ce qui pourrait conduire à une réduction de l'attention portée aux processus ARNi et, par conséquent, à une diminution de l'expression de l'eIF2C2. | ||||||
Geldanamycin | 30562-34-6 | sc-200617B sc-200617C sc-200617 sc-200617A | 100 µg 500 µg 1 mg 5 mg | $38.00 $58.00 $102.00 $202.00 | 8 | |
En inhibant la Hsp90, la geldanamycine peut déstabiliser les protéines associées à l'ARNi, ce qui pourrait entraîner une diminution de la stabilité ou de la synthèse de l'eIF2C2. | ||||||
Silvestrol | 697235-38-4 | sc-507504 | 1 mg | $920.00 | ||
Composé naturel isolé de la plante Aglaia foveolata, connu pour sa puissante inhibition de l'EIF4AI. | ||||||
Rocaglamide | 84573-16-0 | sc-203241 sc-203241A sc-203241B sc-203241C sc-203241D | 100 µg 1 mg 5 mg 10 mg 25 mg | $270.00 $465.00 $1607.00 $2448.00 $5239.00 | 4 | |
Un autre composé naturel trouvé dans plusieurs plantes, telles que le genre Aglaia, avec une forte activité inhibitrice de l'EIF4AI. | ||||||
4E1RCat | 328998-25-0 | sc-361085 sc-361085A | 10 mg 50 mg | $189.00 $797.00 | ||
Inhibiteur synthétique de l'EIF4AI conçu pour perturber le complexe eIF4F, inhibant ainsi la traduction cap-dépendante. |